The PSMA5 (Proteasome Subunit Alpha 5) gene encodes a critical component of the 20S proteasome core particle, the central protease responsible for degrading ubiquitinated proteins in eukaryotic cells. Located at chromosomal position 1p13.3, PSMA5 is one of seven alpha subunits that form the outer regulatory rings of the proteasome barrel structure. This gene is essential for maintaining cellular protein homeostasis in all tissues, with particularly important functions in post-mitotic neurons where protein quality control is crucial for long-term survival.
| Gene Symbol | PSMA5 |
| Full Name | Proteasome Subunit Alpha 5 |
| Chromosomal Location | 1p13.3 |
| NCBI Gene ID | 5686 |
| OMIM | 176845 |
| Ensembl ID | ENSG00000143106 |
| UniProt | P28066 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease |
PSMA5 encodes the alpha subunit type 5 of the 20S proteasome, a 28-subunit protease organized as a four-ring stack (alpha7-beta7-beta7-alpha7). The seven alpha subunits (PSMA1-7) form the outer rings and regulate substrate entry into the proteolytic chamber formed by the seven beta subunits. PSMA5 is unique among the alpha subunits as it contains a specific N-terminal extension that participates in forming the proteasome activation channel[1].
PSMA5 assembles with six other alpha subunits to form the heptameric alpha ring. This ring serves as the gatekeeper for the proteolytic chamber, controlling access of substrates to the catalytic beta subunits. PSMA5 specifically contributes to:
The ubiquitin-proteasome system (UPS) is the primary pathway for regulated protein degradation in eukaryotic cells. PSMA5 plays a central role by:
In neurons, proteasome function is critical for:
Proteasome activity is significantly reduced in Alzheimer's disease brain. Studies have documented decreased PSMA5 expression in AD hippocampus and cortex, contributing to impaired clearance of amyloid-beta and tau proteins. The accumulation of ubiquitinated protein aggregates in AD brain reflects this proteasome dysfunction[4].
alpha-Synuclein, the key protein in Parkinson's disease pathogenesis, is normally degraded by the proteasome. Mutations or reduced activity of proteasome components, including PSMA5, may contribute to alpha-synuclein aggregation and dopaminergic neuron loss in the substantia nigra[5].
Huntington's disease is caused by polyglutamine expansion in the huntingtin protein, which forms toxic aggregates that overwhelm the UPS. Proteasome impairment, including altered PSMA5 expression, has been observed in HD models and patient brain tissue[6].
PSMA5 is ubiquitously expressed with high levels in metabolically active tissues:
Modulating PSMA5 function represents a potential therapeutic strategy for neurodegenerative diseases:
The study of Psma5 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Groll et al. [Crystal Structure of the 20S Proteasome (2000)](https://doi.org/10.1016/S0092-8674(00). 2000. ↩︎
Hershko & Ciechanover, The Ubiquitin System (1998). 1998. ↩︎
Tai & Schuman, Protein Synthesis, Proteasomes, and Synaptic Plasticity (2010). 2010. ↩︎
Gregori et al. Proteasome Alterations in AD Brain (1995). 1995. ↩︎
McNaught & Jenner, Proteasome Function in PD (2001). 2001. ↩︎
Jana et al. Proteasome Impairment in HD (2001). 2001. ↩︎
Schmidt & Finley, Proteasome Activators in Therapy (2014). 2014. ↩︎